Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease in the United States, is a rapidly progressive neurodegenerative disorder characterized by the selective loss of motor neurons in the brain and spinal cord. The disease affects both upper motor neurons (UMNs) in the motor cortex and lower motor neurons (LMNs) in the brainstem and spinal cord, leading to progressive muscle weakness, atrophy, and paralysis. ALS typically manifests in mid-to-late adulthood, with most patients presenting between ages 55 and 75, though early-onset variants occur in younger individuals. The median survival time from symptom onset is approximately 2-4 years, though heterogeneity exists among patient populations. Approximately 10% of ALS cases are familial (fALS), while 90% are sporadic (sALS), though genetic factors increasingly appear to contribute to both forms.
Motor neurons are specialized neurons that directly control voluntary muscle movement. Upper motor neurons originate from the motor cortex and project through the corticospinal tract to synapse on lower motor neurons in the spinal cord. Lower motor neurons receive these signals and directly innervate skeletal muscles through the neuromuscular junction. This hierarchical motor system enables precise, coordinated movement. In ALS, the progressive degeneration of both motor neuron populations disrupts this control system. Early signs often reflect LMN loss, manifesting as fasciculations and focal weakness in limbs or bulbar muscles (speech and swallowing). As disease progresses, UMN involvement produces hyperreflexia and spasticity. The clinical presentation varies based on which motor neurons degenerate first: limb-onset ALS (60% of cases) begins with distal weakness in extremities, while bulbar-onset ALS (25% of cases) affects speech and swallowing muscles initially.
ALS represents a primary disorder of motor neurodegeneration with relatively selective vulnerability of these neurons compared to other neural populations. The reason for this selective vulnerability remains incompletely understood but likely involves motor neuron-specific intrinsic properties and susceptibility factors. Motor neurons are particularly large cells with extensive axonal projections, potentially making them metabolically demanding and susceptible to excitotoxic insults. The disease involves both cell-autonomous mechanisms (within motor neurons themselves) and non-cell-autonomous processes (involving glial cells and immune responses). Progressive motor neuron death leads to denervation of muscles, causing secondary atrophy and functional decline. Unlike some neurodegenerative diseases affecting cognitive function primarily, ALS typically preserves cognitive abilities until late stages, though frontotemporal dementia can occur as part of the ALS-FTD spectrum.
Multiple pathogenic mechanisms contribute to ALS development. Excitotoxicity, driven by excessive glutamate signaling through NMDA and AMPA receptors, leads to calcium overload and neuronal death. Protein aggregation involving TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) represents a hallmark pathology, with abnormal phosphorylation and cytoplasmic accumulation in motor neurons. Over 30 genetic loci are associated with ALS, including SOD1, C9orf72, FUS, and TARDBP genes. The C9orf72 hexanucleotide repeat expansion generates toxic dipeptide repeat proteins through repeat-associated non-ATG translation. Oxidative stress from impaired antioxidant defenses contributes to neuronal injury. Mitochondrial dysfunction, including energy metabolism abnormalities and calcium regulation defects, compromises motor neuron survival. Additionally, compromised proteostasis—the cellular ability to maintain proper protein quality through the ubiquitin-proteasome system and autophagy—allows accumulation of misfolded proteins. Neuroinflammation driven by activated microglia and astrocytes contributes to non-cell-autonomous degeneration.
ALS diagnosis relies on clinical assessment combined with electromyography and imaging to exclude mimics. No cure exists; riluzole and edaravone are FDA-approved disease-modifying agents showing modest survival benefits. Multidisciplinary care addressing respiratory, nutritional, and psychological needs improves quality of life. Research focuses on targeting specific genetic mutations, clearing protein aggregates, modulating immune responses, and preserving neuromuscular junction function. Understanding ALS pathogenesis has broader implications for other neurodegenerative diseases sharing TDP-43 pathology, including Alzheimer's disease and frontotemporal dementia.
[[Motor Neurons]], [[Neurodegeneration]], [[TDP-43]], [[SOD1]], [[C9orf72]], [[Neuroinflammation]], [[Protein Aggregation]], [[Excitotoxicity]], [[Frontotemporal Dementia]], [[Neuromuscular Junction]]